European Journal of Clinical Pharmacology

, Volume 13, Issue 1, pp 1–4 | Cite as

Intrinsic sympathomimetic activity ofβ-adrenoceptor blocking agents

  • G. Cocco
  • F. Burkart
  • D. Chu
  • F. Follath
Originals

Summary

The pharmacological methods used to assess the intrinsic sympathomimetic activity (ISA) of β-blockers are discussed. The clinical relevance of ISA to respiratory function, peripheral resistance and cardiac function is reviewed. It appears doubtful whether ISA is always of predominant clinical significance and an alternative explanation is offered for many clinical effects observed with certain β-blockers, e.g. pindolol, oxprenolol, tolamolol, metoprolol, etc. Some effects of these β-blockers resemble those of labetalol, a new drug with both α- and β-blocking activity. Some clinical effects of certain β-blockers are more likely to be due to α-blocking activity than to their ISA.

Key words

β-Blockers α-blocking activity intrinsic sympathomimetic activity partial agonist 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ablad, B., Brogard, M., Ek, L.: Pharmacological properties of H 56/28 — a β-adrenergic receptor antagonist. Acta pharmacol. toxicol.,25, Suppl. 2, 9–40 (1967)Google Scholar
  2. 2.
    Ablad, B., Carlsson, E., Ek, L.: Pharmacological studies of two new cardioselective adrenergic β-receptor antagonists. Life Sci.12, 107–119 (1973)Google Scholar
  3. 3.
    Ablad, B., Carlsson, E., Dahlof, C., Ek, L.: Some aspects of the pharmacology of β-adrenoceptor blockers. Drugs11, Suppl. 1, 100–111 (1976)Google Scholar
  4. 4.
    Adam, K.R., Baird, J.R.C., Burges, R.A., Linnell, J.: The β-blocking potency and cardioselectivity of tolamolol and its isomers in rodents. Eur. J. Pharmacol.,25, 170–175 (1974)Google Scholar
  5. 5.
    Ahlquist, R.P.: Present state of α- and β-adrenergic drugs II. The adrenergic blocking agents. Am. Heart J.,92, 804–807 (1976)Google Scholar
  6. 6.
    Atterhög, J.H., Dunér, H., Pernow, W.: Experience with pindolol, a β-receptor blocker in the treatment of hypertension. Amer. J. Med.,60, 872–876 (1976)Google Scholar
  7. 7.
    Barrett, A.M.: A survey of the pharmacological properties of adrenergic β-receptor antagonists. Int. J. clin. Pharmacol.,3, Suppl. 3, 2–16 (1970)Google Scholar
  8. 8.
    Barrett, A.M., Carter, J.: Comparative chronotropic activity of β-adrenoceptor antagonists. Brit. J. Pharmacol.,40, 373–381 (1970)Google Scholar
  9. 9.
    Barrett, A.M., Carter, J., Fitzgerald, J.D., Hull, R., Le Count, D.: A new type of cardioselective adrenoceptive blocking drugs. Brit. J. Pharmacol.,48, 340-P (1973)Google Scholar
  10. 10.
    Basil, B., Jordan, R., Loveless, A.H., Maxwell, D.R.: β-adrenoceptor blocking properties and cardioselectivity of M & B 17, 803A. Brit. J. Pharmacol.,48, 198–211 (1973)Google Scholar
  11. 11.
    Beumer, H.M.: Adverse effects of β-adrenergic receptor blocking drugs on respiratory function. Drugs7, 130–138 (1974)Google Scholar
  12. 12.
    Black, J.W., Stephenson, J.S.: Pharmacology of a new adrenergic β-receptor-blocking compound (nethalide). Lancet1962 II, 311–314Google Scholar
  13. 13.
    Blum, J., Atsmon, A., Steiner, M., Wysenbeek, H.: Paradoxical rise in blood pressure during propranolol treatment. Brit. med. J. 1975,4, 623Google Scholar
  14. 14.
    Briant, R.H., Dollery, C.T., George, C.F.: The selectivity of acebutolol. Clin. Trials J.3, 25–28 (1974)Google Scholar
  15. 15.
    Brittain, R.T., Levy, G.P.: A review of the animal pharmacology of labetolol, a combined α- and β-adrenoceptor-blocking drug. Brit. J. clin. Pharmacol., Suppl., 681–694 (1976)Google Scholar
  16. 16.
    Bühler, F.R., Laragh, J.H., Vaughan, E.D., Brunner, H.R., Gavras, H., Baer, L.: The antihypertensive action of propranolol, pp. 873–898. In: Hypertension Manual (ed. J.H. Laragh) New York: Yorke Med. Books: Don-Donnelley Publ. Corp. 1974Google Scholar
  17. 17.
    Bühler, F.R., Burkart, F., Lütold, B.E., Küng, M., Marbet, G., Pfisterer, M.: Antihypertensive β-blocking action as related to renin and age: a pharmacologic tool to identify pathogenic mechanisms in essential hypertension. Amer. J. Cardiol.36, 653–669 (1975)Google Scholar
  18. 18.
    Bühler, F.R., Marbet, G., Patel, U., Burkart, F.: Renin-suppressive potency of various β-adrenergic blocking agents at supine rest and during upright exercise. Clin. Sci. Molec. Med.48, Suppl. 2, 61–64 (1975)Google Scholar
  19. 19.
    Bühler, F. R., Lütold, B.E.: β-Adrenerge Rezeptorblockade als Basis der Hypertoniebehandlung. Therap. Umschau33, 336–346 (1976)Google Scholar
  20. 20.
    Cocco, G., Strozzi, C., Chu, D.: I farmaci β-bloccanti sono stati introdotti in clinica 15 anni or sono: miti e realtà. Clin. Ter.80, 67–89 (1977)Google Scholar
  21. 21.
    Davidson, C., Thadani, U., Singleton, W., Taylor, S.H.: Comparison of antihypertensive activity of β-blocking drugs during chronic treatment. Brit. med. J.1976 2, 7–9Google Scholar
  22. 22.
    De White, C. B., Udwadia, B. P.: β-adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline. Brit. J. clin. Pharmacol.2, 99–105 (1975)Google Scholar
  23. 23.
    Dollery, C. T., Paterson, J. W., Conolly, M. E.: Clinical pharmacology of β-receptor blocking drugs. Clin. Pharmacol. Therap.10, 765–799 (1969)Google Scholar
  24. 24.
    Doyle, A. E.: Use of β-adrenoreceptor blocking drugs in hypertension. Curr. Ther.15, 85–92 (1974)Google Scholar
  25. 25.
    Drayer, J. I. M., Keim, H. J., Weber, M. A., Case, D. B., Laragh, J. H.: Unexpected pressor responses to propranolol in essential hypertension. Amer. J. Med.60, 897–903 (1976)Google Scholar
  26. 26.
    Dubach, U. C.: Was ist von Kardioselektivität und sympathikomimetischer Eigenwirkung von β-Rezeptorenblockern zu halten? Schweiz. Rundschau Med.64, 1239–1241 (1975)Google Scholar
  27. 27.
    Epstein, S. E., Braunwald, E.: β-adrenergic receptor blocking drugs. New Engl. J. Med.275, 1175–1183 (1966)Google Scholar
  28. 28.
    Gabriel, R.: Letter to the Editor. Brit. med. J.1976, 1, 219Google Scholar
  29. 29.
    Govier, W. C., Mosal, N. C., Whrittmyon, P., Broom, A. H.: Myocardial α and β adrenergic receptors as demonstrated by atrial functional refractory-period changes. J. Pharmacol. exp. Ther.154, 255–263 (1966)Google Scholar
  30. 30.
    Hagino, H. Y.: Relationship between thyroid function and catecholamine effects. Jap. J. Pharmacol.26, Suppl. 32 (1976)Google Scholar
  31. 31.
    Heierli, C., Thölen, H., Radielovic, P.: Renal function after a single oral dose of pindolol in patients suffering from hypertension and chronic renal failure. Kidney7, 365 (1976)Google Scholar
  32. 32.
    Julien, J., Vallat, J. M., Lagueny, A., Darriet, D.: Le traitement prophylactique des migraines par le propranolol. Nouv. Presse méd.5, 653 (1976)Google Scholar
  33. 33.
    Koch, G.: Haemodynamic effects of combined α- and β-adrenoceptor blockade after intravenous labetolol in hypertensive patients at rest and during exercise. Brit. J. clin. Pharmacol., Suppl.I, 725–728 (1976)Google Scholar
  34. 34.
    Koch, G.: Combined α- and β-adrenoceptor blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise. Brit. J. clin. Pharmacol., Suppl.I, 729–732 (1976)Google Scholar
  35. 35.
    Kumana, C. R., Kaye, C. M., Leighton, M., Turner, P., Hamer, J.: Cardiac and pulmonary effects of acebutolol. Lancet1975, II, 89–93Google Scholar
  36. 36.
    Kunos, G., Szentivanyi, M.: Evidence favouring the existence of a single adrenergic receptor. Nature (London)217, 1077–1078 (1968)Google Scholar
  37. 37.
    Kunos, G., Nickerson, M., Aranda, J. V., Boyd, G. N.: Properties of myocardial adrenoceptors in altered thyroid. Pharmacologist16, 290 (1974)Google Scholar
  38. 38.
    Lewis, P.: The essential action of propranolol in hypertension. Amer. J. Med.60, 837–852 (1976)Google Scholar
  39. 39.
    Lorimer, A. R., Dunn, F. G., Jones, J. V., Veitch Lauwrie, T. D.: β-adrenoceptor blockade in hypertension. Amer. J. Med.60, 877–885 (1976)Google Scholar
  40. 40.
    Marbet, G., Bühler, F. R., Burkart, F.: Renin suppression of eightβ-blockers compared at different levels ofβ-adrenergic nerve activity. Kidney7, 366 (1975)Google Scholar
  41. 41.
    Metha, J. L., Cohn, J. N.: Dissociation of inotropic from chronotropic effects of isoproterenol during β-blockade with labetalol. Clin. Res.24, 423 (1976)Google Scholar
  42. 42.
    Morgan, T. O., Anavekar, S. N., Sabto, J., Louis, W. J.: A comparison of β adrenergic blocking drugs in the treatment of hypertension. Postgrad. med. J.50, 253–259 (1974)Google Scholar
  43. 43.
    Nussberger, J., Vetter, W., Krayenbühl, H. P., Siegenthaler, W.: Einfluß der β-Rezeptorenbehandlung mit Pindolol auf Plasmareninaktivität und linksventrikuläre Dynamik bei essentieller Hypertonie. Kardiol. Jahresversammlung, Schweiz. Gesell. Inn. Med., Lugano 5–7/June/1975, Communic. No. 16, p. 16Google Scholar
  44. 44.
    Prichard, B. N. C.: β-adrenergic receptor blocking drugs in angina pectoris. Drugs7, 55–84 (1974)Google Scholar
  45. 45.
    Rand, M. J., Law, M., Story, D. F., McCulloch, M. W.: Effects of β-adrenoreceptor blocking drugs on adrenergic transmission. Drugs11, Suppl. 1, 134–143 (1976)Google Scholar
  46. 46.
    Saameli, K.: Comparative studies with β-receptor blocking agents and quinidine. Helv. Physiol. Acta25, 432–433 (1967)Google Scholar
  47. 47.
    Shand, D. V.: Drug therapy, Propranolol. New Engl. J. Med.293, 280–285 (1975)Google Scholar
  48. 48.
    Siegl, H., Clark, B.: Renal actions of β-adrenoceptor blocking agents in the rat. 6th Intern. Congr. Pharmacol., Helsinki, 20–25/June/1975, Abstr. p. 250Google Scholar
  49. 49.
    Singh, B. N., Hauswirth, O.: Comparative mechanisms of action of antiarrhythmic drugs. Amer. Heart J.87, 367–382 (1974)Google Scholar
  50. 50.
    Singh, B. N., Whitlock, R. M. L., Russell, H. C., Williams, F. H., Harris, E. A.: Effects of cardioselective β adrenoceptor blockade on specific airway resistance in normal subjects and in patients with bronchial asthma. Clin. Pharmacol. Ther.19, 493–501 (1976)Google Scholar
  51. 51.
    Skinner, C., Palmer, K. N. V.: Airways obstruction in asthmatics: comparison of the effects of acebutolol, practolol and placebo. Clinical Trials J.3, 29–31 (1974)Google Scholar
  52. 52.
    Skinner, C., Gaddie, J., Palmer, N. K. V.: Comparison of intravenous AH 5158 (Ibidomide) and propranolol in asthma. Brit. Med. J.1975, 2, 59–61Google Scholar
  53. 53.
    Stokes, G. S., Weber, M. A., Thornell, I. R.: β-blockers and plasma renin activity in hypertension. Brit. Med. J.1974, 1, 60–62Google Scholar
  54. 54.
    Stokes, G. S., Graham, R. M., Weber, M. A.: The role of renin in the antihypertensive action of β-adrenoreceptor blocking agents. Drugs11, Suppl. 1, 150–156 (1976)Google Scholar
  55. 55.
    Stumpe, K. O., Vetter, V., Hessenbruch, V., Düsing, R., Kolloch, R., Krück, F.: Einfluß einer chronischen β-Rezeptoren-blockade auf Blutdruck, Renin-, Aldosteron- und Cortisolsekretion bei essentieller Hypertension. Klin. Wschr.53, 907–911 (1975)Google Scholar
  56. 56.
    Taylor, S. H.: Seite 48 in: Die Betablocker. Gegenwart und Zukunft. W. Schweizer, Ed., Basler Verlag Hans Huber, 1976Google Scholar
  57. 57.
    Vatner, S. F., Braunwald, E.: Cardiovascular control mechanisms in the conscious state. New Engl. J. Med.293, 970–976 (1975)Google Scholar
  58. 58.
    Waal-Manning, H. J.: Hypertension: which β-blocker? Drugs12, 412–441 (1976)Google Scholar
  59. 59.
    Trendelenburg, U.: An analysis of the α- and β-effects of isoprenaline on the isolated nictitating membrane. Naunyn-Schmiedeberg's Arch. Pharmacol.285, 375–393 (1973)Google Scholar
  60. 60.
    van den Brink, F. G.: The model of functional interaction. II. Experimental verification of a new model: the antagonism of β-adrenoceptor stimulants and other agonists. Europ. J. Pharmacol.22, 279–286 (1973)Google Scholar
  61. 61.
    Waal-Manning, H. J., Simpson, F. O.: Paradoxical effect of pindolol. Br. Med. J.3, 155–156 (1975)Google Scholar
  62. 62.
    Zaimis, E.: On the pharmacology of β-receptor blocking drugs. Cardiovascular Regulation, pp. 189–195, 1st Internat. Symp. of the Cardiovascular Res. Inst., Univ. of Milan, 17/9/1970, Bartorelli & Zanichetti Ed.Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • G. Cocco
    • 1
  • F. Burkart
    • 1
  • D. Chu
    • 2
  • F. Follath
    • 3
  1. 1.Cardiological Laboratory, KantonsspitalUniversity of BasleSwitzerland
  2. 2.SonnenrainZwingenSwitzerland
  3. 3.Clinical Pharmacology Department, KantonsspitalUniversity of BasleSwitzerland

Personalised recommendations